Search research articles
Contact Us
Filters
Showing results (51-60 of 63) with videos related to
Page
of 7
Sort By:
Breast Cancer Research and Treatment
|
February 5, 2010
Mammographic density does not differ between unaffected BRCA1/2 mutation carriers and women at low-to-average risk of breast cancer
Gretchen L Gierach, Jennifer T Loud, Catherine K Chow, et al.
Iscience
|
September 9, 2024
Multiplex imaging of localized prostate tumors reveals altered spatial organization of AR-positive cells in the microenvironment
Çiğdem Ak, Zeynep Sayar, Guillaume Thibault, et al.
Science Translational Medicine
|
September 21, 2022
Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer
Jackson Liang, Ellen Rei Ingalla, Xiaosai Yao, et al.
Breast Cancer Research : BCR
|
August 28, 2014
Relationships between computer-extracted mammographic texture pattern features and BRCA1/2 mutation status: a cross-sectional study
Gretchen L Gierach, Hui Li, Jennifer T Loud, et al.
JAMA Oncology
|
October 25, 2019
Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial
Zhimin Shao, Da Pang, Hongjian Yang, et al.
Nature Communications
|
March 31, 2026
Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER<sup>+</sup> HER2<sup>-</sup> locally-advanced or metastatic breast cancer
Jackson Liang, Christy Ong, Kareem Heslop, et al.
Molecular Cancer Therapeutics
|
December 5, 2024
First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain-Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors
Melissa L Johnson, Beni B Wolf, Judy S Wang, et al.
JCI Insight
|
April 22, 2021
The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer
Michalina Janiszewska, Shayna Stein, Otto Metzger Filho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2023
Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer
Komal L Jhaveri, Meritxell Bellet, Nicholas C Turner, et al.
Nature Communications
|
September 13, 2023
MYC Deregulation and PTEN Loss Model Tumor and Stromal Heterogeneity of Aggressive Triple-Negative Breast Cancer
Zinab O Doha, Xiaoyan Wang, Nicholas L Calistri, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 63) with videos related to
Sort By:
Page
of 7
Breast Cancer Research and Treatment
|
February 5, 2010
Mammographic density does not differ between unaffected BRCA1/2 mutation carriers and women at low-to-average risk of breast cancer
Gretchen L Gierach, Jennifer T Loud, Catherine K Chow, et al.
Iscience
|
September 9, 2024
Multiplex imaging of localized prostate tumors reveals altered spatial organization of AR-positive cells in the microenvironment
Çiğdem Ak, Zeynep Sayar, Guillaume Thibault, et al.
Science Translational Medicine
|
September 21, 2022
Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer
Jackson Liang, Ellen Rei Ingalla, Xiaosai Yao, et al.
Breast Cancer Research : BCR
|
August 28, 2014
Relationships between computer-extracted mammographic texture pattern features and BRCA1/2 mutation status: a cross-sectional study
Gretchen L Gierach, Hui Li, Jennifer T Loud, et al.
JAMA Oncology
|
October 25, 2019
Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial
Zhimin Shao, Da Pang, Hongjian Yang, et al.
Nature Communications
|
March 31, 2026
Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER<sup>+</sup> HER2<sup>-</sup> locally-advanced or metastatic breast cancer
Jackson Liang, Christy Ong, Kareem Heslop, et al.
Molecular Cancer Therapeutics
|
December 5, 2024
First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain-Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors
Melissa L Johnson, Beni B Wolf, Judy S Wang, et al.
JCI Insight
|
April 22, 2021
The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer
Michalina Janiszewska, Shayna Stein, Otto Metzger Filho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2023
Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer
Komal L Jhaveri, Meritxell Bellet, Nicholas C Turner, et al.
Nature Communications
|
September 13, 2023
MYC Deregulation and PTEN Loss Model Tumor and Stromal Heterogeneity of Aggressive Triple-Negative Breast Cancer
Zinab O Doha, Xiaoyan Wang, Nicholas L Calistri, et al.
Page
of 7